Multiple Myeloma

A recently published study reveals key factors contributing to the underutilization of treatment in multiple myeloma patients. The study emphasizes the importance of understanding patients’ perceptions, the role of physician recommendations, and individual decision-making preferences. Treatment underutilization in multiple myeloma is influenced by patient perceptions, doctor recommendations, and individual decision-making practices. No racial differences were...

Recent advancements in CAR-T cell therapies have shown encouraging results for patients with relapsed/refractory multiple myeloma. While the promise is high, barriers like manufacturing availability and socioeconomic disparities pose challenges to making these treatments widely accessible. Two CAR-T cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, have shown positive outcomes in patients with poor prognosis. Barriers...

A systematic review reveals disparities in the incidence, treatment, and outcomes of Hispanic Americans with multiple myeloma. These disparities may indicate an urgent need for structural solutions to ensure equitable healthcare access for this demographic. Hispanic Americans face health disparities in multiple myeloma, exhibiting worse clinical outcomes than other ethnic groups. The incidence of multiple...

Multiple myeloma is a serious health issue. It is a form of cancer that develops within bone marrow due to genetic mutations.  So, since this cancer develops from genetic mutations, does that mean it is hereditary? This article will explore the answer to this question while also looking at other risk factors.  What Is Multiple...

Daratumumab with bortezomib and dexamethasone significantly increased the overall survival in patients suffering from relapsed or refractory multiple myeloma. Daratumumab is a human monoclonal CD38 antibody that poses greater cytotoxicity against multiple myeloma cells than other CD38 antibodies. Adding this drug to the standard treatment regimen for multiple myeloma significantly improves the durability of response...

This phase 1 study demonstrated that chimeric antigen receptor T completely synthetic antigen-binding domain cell therapy is safe and has a durable response in patients with relapsed and refractory multiple myeloma. Relapsed and refractory multiple myeloma (RRMM) is a progressively refractory disease requiring chronic intensive therapy. This phase 1 study aimed to assess the safety...

Reduced global longitudinal strain indicates reduced survival in patients with multiple myeloma. Patients suffering from multiple myeloma (MM) are at significantly higher risk for developing cardiac pathology due to multiple disease- and treatment-related factors as well as old age. The prognosis for these patients can be improved by earlier detection of cardiac disease. Left ventricular...

Pomalidomide, bortezomib, and dexamethasone combination chemotherapy is efficacious and safe for the treatment of newly diagnosed multiple myeloma. Multiple myeloma (MM) is an incurable disease. Currently, treatment aims to improve the quality of life and overall survival of these patients. The established standard treatment in newly diagnosed multiple myeloma (NDMM) cases consists of bortezomib, lenalidomide,...

No cures exist for multiple myeloma, but the latest advances in treatments and research into the disease offer hope to those affected. Researchers have uncovered treatments that have increased remission rates, extended life expectancy, and even improved quality of life for multiple myeloma patients. Multiple Myeloma (MM) is a cancer of the plasma cells. These...